Grant: Operating Grant - PA: Musculoskeletal Health, Arthritis, Skin and Oral Health
McGill University
$100,000.00
The alphaNAC transcriptional coregulator as a downstream effector of PTH action in bone
EF 2010-11
Résumé
Osteoporosis, the most prevalent metabolic bone disease, affects the elderly. Daily subcutaneous injection ('intermittent treatment') with human parathyroid hormone (PTH) (Teriparatide or Fortéo®) is the only approved treatment for increasing bone mass in osteoporosis patients. The mechanisms involved in the bone-forming effects of intermittent PTH treatment are not fully understood. Our major research focus involves further characterization of the signal transduction pathways acting downstream from PTH receptor activation. We have identified a novel signalling cascade that initiates with PTH binding to its receptor and culminates with the subcellular relocalization of the transcriptional regulator alphaNAC to the nucleus to regulate Osteocalcin gene transcription. We plan to use a comprehensive array of cellular, molecular, and genetic approaches to demonstrate that the PTH-induced cascade that sends alphaNAC to the nucleus mediates the bone-forming action of PTH. Once we establish this sequence of actions and the functions and mechanisms are known, this pathway has the potential to be used as a target for the development of therapeutics for osteoporosis.
Programme
Operating Grant - PA: Musculoskeletal Health, Arthritis, Skin and Oral Health
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
219745
Name
St-Arnaud René
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Endocrinology
Projecttitle
The alphaNAC transcriptional coregulator as a downstream effector of PTH action in bone
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Musculoskeletal Health, Arthritis, Skin and Oral Health
Keyworddelim
Animal Models Of Bone Disease; Bone Anabolic Effect Of Pth; Gene Expression Monitoring; Gene Transcription; Knockin Mouse Mutagenesis; Osteoporosis; Parathyroid Hormone; Signal Transduction
Abstract
Osteoporosis, the most prevalent metabolic bone disease, affects the elderly. Daily subcutaneous injection ('intermittent treatment') with human parathyroid hormone (PTH) (Teriparatide or Fortéo®) is the only approved treatment for increasing bone mass in osteoporosis patients. The mechanisms involved in the bone-forming effects of intermittent PTH treatment are not fully understood. Our major research focus involves further characterization of the signal transduction pathways acting downstream from PTH receptor activation. We have identified a novel signalling cascade that initiates with PTH binding to its receptor and culminates with the subcellular relocalization of the transcriptional regulator alphaNAC to the nucleus to regulate Osteocalcin gene transcription. We plan to use a comprehensive array of cellular, molecular, and genetic approaches to demonstrate that the PTH-induced cascade that sends alphaNAC to the nucleus mediates the bone-forming action of PTH. Once we establish this sequence of actions and the functions and mechanisms are known, this pathway has the potential to be used as a target for the development of therapeutics for osteoporosis.
Competitiondate
201009
Approvedterm2
1 yr 0 mth
Pinamesdelim
St-Arnaud, René
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~